Retrospective study comparing irinotecan and pegylated liposomal doxorubicin in treatment of recurrent platinum-refractory/resistant epithelial ovarian cancer

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Purpose: The standard regimen for platinum-resistant/refractory recurrent epithelial ovarian cancer (EOC) remains to be determined. In this study, we retrospectively compared the effect of irinotecan (CPT-11) and pegylated liposomal doxorubicin (PLD) in the treatment of platinum-resistant recurrent EOC. Methods: Thirty patients who received salvage chemotherapy with CPT-11 or PLD were included in the study. CPT-11 (100 mg/m 2) was administered intravenously on days 1, 8 and 15 every four weeks. PLD (50 mg/m 2) was administered on day 1 every four weeks. Treatment was repeated, provided that no disease progression or intolerable toxicity occurred. Results: Response rate in the CPT-11 group and PLD group showed no difference at 26.7% (p = 0.66) in both, while non-PD rate was 73.3% vs 33.3% (p < 0.05), respectively. Progression-free survival after CPT-11 treatment and PLD treatment was 28.4 weeks and 16.8 weeks (p = 0.07), respectively. Hand-foot syndrome and mucositis were more common in the PLD group than in the CPT-11 group (p < 0.05). Conclusions: The results indicate that CPT-11 is a promising drug for the treatment of platinum-resistant recurrent EOC.

Original languageEnglish
Pages (from-to)86-89
Number of pages4
JournalEuropean Journal of Gynaecological Oncology
Volume33
Issue number1
Publication statusPublished - 2012

Fingerprint

irinotecan
Platinum
Retrospective Studies
Therapeutics
Hand-Foot Syndrome
Mucositis
liposomal doxorubicin
Ovarian epithelial cancer

Keywords

  • Irinotecan
  • Liposomal doxorubicin
  • Ovarian cancer
  • Platinum-resistant
  • Recurrence

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology

Cite this

@article{260d6a9f5cbb44818e3c487795c23d99,
title = "Retrospective study comparing irinotecan and pegylated liposomal doxorubicin in treatment of recurrent platinum-refractory/resistant epithelial ovarian cancer",
abstract = "Purpose: The standard regimen for platinum-resistant/refractory recurrent epithelial ovarian cancer (EOC) remains to be determined. In this study, we retrospectively compared the effect of irinotecan (CPT-11) and pegylated liposomal doxorubicin (PLD) in the treatment of platinum-resistant recurrent EOC. Methods: Thirty patients who received salvage chemotherapy with CPT-11 or PLD were included in the study. CPT-11 (100 mg/m 2) was administered intravenously on days 1, 8 and 15 every four weeks. PLD (50 mg/m 2) was administered on day 1 every four weeks. Treatment was repeated, provided that no disease progression or intolerable toxicity occurred. Results: Response rate in the CPT-11 group and PLD group showed no difference at 26.7{\%} (p = 0.66) in both, while non-PD rate was 73.3{\%} vs 33.3{\%} (p < 0.05), respectively. Progression-free survival after CPT-11 treatment and PLD treatment was 28.4 weeks and 16.8 weeks (p = 0.07), respectively. Hand-foot syndrome and mucositis were more common in the PLD group than in the CPT-11 group (p < 0.05). Conclusions: The results indicate that CPT-11 is a promising drug for the treatment of platinum-resistant recurrent EOC.",
keywords = "Irinotecan, Liposomal doxorubicin, Ovarian cancer, Platinum-resistant, Recurrence",
author = "Hiroyuki Nomura and H. Tsuda and Fumio Kataoka and Tatsuyuki Chiyoda and Wataru Yamagami and Eiichirou Tominaga and N. Susumu and Daisuke Aoki",
year = "2012",
language = "English",
volume = "33",
pages = "86--89",
journal = "European Journal of Gynaecological Oncology",
issn = "0392-2936",
publisher = "S.O.G. CANADA Inc.",
number = "1",

}

TY - JOUR

T1 - Retrospective study comparing irinotecan and pegylated liposomal doxorubicin in treatment of recurrent platinum-refractory/resistant epithelial ovarian cancer

AU - Nomura, Hiroyuki

AU - Tsuda, H.

AU - Kataoka, Fumio

AU - Chiyoda, Tatsuyuki

AU - Yamagami, Wataru

AU - Tominaga, Eiichirou

AU - Susumu, N.

AU - Aoki, Daisuke

PY - 2012

Y1 - 2012

N2 - Purpose: The standard regimen for platinum-resistant/refractory recurrent epithelial ovarian cancer (EOC) remains to be determined. In this study, we retrospectively compared the effect of irinotecan (CPT-11) and pegylated liposomal doxorubicin (PLD) in the treatment of platinum-resistant recurrent EOC. Methods: Thirty patients who received salvage chemotherapy with CPT-11 or PLD were included in the study. CPT-11 (100 mg/m 2) was administered intravenously on days 1, 8 and 15 every four weeks. PLD (50 mg/m 2) was administered on day 1 every four weeks. Treatment was repeated, provided that no disease progression or intolerable toxicity occurred. Results: Response rate in the CPT-11 group and PLD group showed no difference at 26.7% (p = 0.66) in both, while non-PD rate was 73.3% vs 33.3% (p < 0.05), respectively. Progression-free survival after CPT-11 treatment and PLD treatment was 28.4 weeks and 16.8 weeks (p = 0.07), respectively. Hand-foot syndrome and mucositis were more common in the PLD group than in the CPT-11 group (p < 0.05). Conclusions: The results indicate that CPT-11 is a promising drug for the treatment of platinum-resistant recurrent EOC.

AB - Purpose: The standard regimen for platinum-resistant/refractory recurrent epithelial ovarian cancer (EOC) remains to be determined. In this study, we retrospectively compared the effect of irinotecan (CPT-11) and pegylated liposomal doxorubicin (PLD) in the treatment of platinum-resistant recurrent EOC. Methods: Thirty patients who received salvage chemotherapy with CPT-11 or PLD were included in the study. CPT-11 (100 mg/m 2) was administered intravenously on days 1, 8 and 15 every four weeks. PLD (50 mg/m 2) was administered on day 1 every four weeks. Treatment was repeated, provided that no disease progression or intolerable toxicity occurred. Results: Response rate in the CPT-11 group and PLD group showed no difference at 26.7% (p = 0.66) in both, while non-PD rate was 73.3% vs 33.3% (p < 0.05), respectively. Progression-free survival after CPT-11 treatment and PLD treatment was 28.4 weeks and 16.8 weeks (p = 0.07), respectively. Hand-foot syndrome and mucositis were more common in the PLD group than in the CPT-11 group (p < 0.05). Conclusions: The results indicate that CPT-11 is a promising drug for the treatment of platinum-resistant recurrent EOC.

KW - Irinotecan

KW - Liposomal doxorubicin

KW - Ovarian cancer

KW - Platinum-resistant

KW - Recurrence

UR - http://www.scopus.com/inward/record.url?scp=84860609385&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860609385&partnerID=8YFLogxK

M3 - Article

VL - 33

SP - 86

EP - 89

JO - European Journal of Gynaecological Oncology

JF - European Journal of Gynaecological Oncology

SN - 0392-2936

IS - 1

ER -